Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia.
Employment has been increasingly recognized as an important goal for individuals with schizophrenia. Previous research has shown mixed results on the relationship of specific antipsychotic medications to employment outcomes, with some studies finding greater benefits for second-generation antipsychotic medications (SGAs) over first-generation antipsychotic medication (FGAs). A randomized controlled trial (CATIE) examined medication assignment and both employment outcomes and participation in psychosocial rehabilitation (PSR) among 1,121 individuals with a diagnosis of schizophrenia randomized to SGAs (olanzapine, quetiapine, risperidone, ziprasidone) or one FGA (perphenazine). Service use and employment were assessed at quarterly interviews. There were no differences between medication groups on employment outcomes or participation in PSR. Consistent with other CATIE results, there were no differences in employment or participation in PSR among these five medications, including the FGA perphenazine.
Resnick
Sandra G
SG
New England Mental Illness Research Education and Clinical Center, Yale University School of Medicine, VA Connecticut Health Care System, NEPEC (182), 950 Campbell Ave., West Haven, CT 06516, USA. Sandy.Resnick@Yale.Edu
Rosenheck
Robert A
RA
Canive
Jose M
JM
De Souza
Cyril
C
Stroup
T Scott
TS
McEvoy
Joseph
J
Davis
Sonia
S
Keefe
Richard S E
RS
Swartz
Marvin
M
Lieberman
Jeffrey
J
D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D004651:Employment; D005260:Female; D006801:Humans; D007407:Interviews as Topic; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D010546:Perphenazine / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*
D014150:Antipsychotic Agents; D010546:Perphenazine